SQZ-eAPC-HPV is an improved 2nd generation product, with no HLA restrictions, that builds on the clinical and manufacturing experience with the 1st generation SQZ-PBMC-HPV product.

Co-localizing these signals on the eAPC surface may enable more potent T cell stimulation and limit off-target effects from systemic exposure to signal 2 and 3. To create enhanced APCs (eAPCs) from peripheral blood mononuclear cells (PBMCs), we used the Cell Squeeze® technology to deliver mRNAs encoding HPV16 E6 and E7 antigens (signal 1), CD86 (signal 2), and membrane-bound IL-2 and IL-12 cytokines (signal 3). Creation of T cell responses requires 3 key signals from antigen presenting cells (APCs): (signal 1) the peptide-MHC complex binding to the T cell receptor, (signal 2) costimulatory molecules that bind to T cell stimulatory domains, and (signal 3) inflammatory cytokines binding to receptors on T cells. Background Antigen-specific CD8+ T cells are critical for mounting a potent immune response against tumors.

Solid commander